Intralesional Injection of Triamcinolone Acetonide for Subcutaneous Lipoma causing Musculoskeletal and Neurologic Symptoms

The Journal of Clinical and Aesthetic Dermatology

William A. Hayward¹  R²  Wilmer L. Sibbitt³ 

[1] Dr. Hayward is with the Department of Exercise and Sport Sciences at New Mexico Highlands University in Las Vegas, New Mexico.;Dr. R. Sibbitt is with Montana Interventional and Diagnostic Radiology in Helena, Montana. Ms. Kettwich is with the School of Dentistry at Oregon Health Science University in Portland, Oregon.;Drs. W. Sibbitt, Muruganandam, Rolle, and Fangtham are with the Department of Internal Medicine, Division of Rheumatology and School of Medicine at University of New Mexico Health Sciences Center in Albuquerque, New Mexico.

关键词: Lipoma;    musculoskeletal;    injection;    corticosteroids;    neurologic;   

DOI  :  

学科分类：医学（综合）

来源: Matrix Medical Communications, LLC

【 摘 要 】

Objective: Benign subcutaneous lipomas can cause musculoskeletal pain and nerve impingement. We hypothesized that the potent lipolytic and atrophic effect of 40mg/mL triamcinolone acetonide would atrophy symptomatic lipomas so surgical excision could be avoided. Design: This was a cohort study. Setting: This study took place in an ultrasound injection clinic. Participants: Eight subjects with painful symptomatic lipoma were included. Measurements: Preprocedurally, the margins of the lipomas were palpated and marked with ink, then measured in centimeters (cm). Small lipomas (1–3cm) were injected with 40mg triamcinolone acetonide, while large lipomas (4–6cm) were injected with 80mg of triamcinolone acetonide. The subjects were reassessed at a four-month follow-up appointment and then again at one year and two years after the procedure. Results: Pre-injection, all eight subjects had symptoms related to impingement or pain with compression of the lipoma. At four months post-injection, none of the patients had symptoms attributable to the lipoma (p<0.001). The mean lipoma palpable dimension was 5.0±1.2cm prior to the injection and was 2.0±1.1cm at four months after the injection, with a significant mean 3.0±0.3cm (60%) reduction in lipoma dimensions (p<0.001). Two subjects demonstrated some mild hypopigmentation of the skin at four months post-injection. Within two years, three lipomas had symptomatically recurred, one of which was removed surgically and the two of which were reinjected. There were no infections or other serious adverse reactions that occurred. Conclusions: For individuals with painful subcutaneous lipoma, intralesional injection of 40mg/mL of triamcinolone acetonide is an effective and safe alternative to surgical excision or injection of sclerosing agents and should be considered as a reasonable therapeutic alternative in select patients.

【 授权许可】

Unknown